Summary

The 7 major substance use disorder markets reached a value of US$ 5.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.63% during 2024-2034.

The substance use disorder market has been comprehensively analyzed in IMARC's new report titled "Substance Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Substance use disorder (SUD) refers to a chronic, relapsing medical condition that is characterized by compulsive drug or alcohol usage. It can have a significant impact on an individual's physical and mental health, relationships, work, and overall quality of life. Substance use disorder can develop through recreational drug use or by prolonged consumption of prescribed medications, such as painkillers. Symptoms of the condition can vary depending on the substance used, the frequency and amount of use, and the individual's medical and personal history. Some of the common symptoms of SUD are strong urges to consume drugs or alcohol, continued substance use despite negative consequences, withdrawal signs like anxiety, agitation, insomnia, physical symptoms like nausea and sweating, etc. Other indications include social, legal, and financial problems, strained relationships with family and friends, etc. Diagnosis of SUD usually involves a thorough evaluation by a healthcare professional, including medical history, physical examination, and behavioral assessment.

The rising usage of prescription/illicit drugs coupled with the increasing consumption of tobacco and alcohol is primarily driving the global substance use disorder market. In addition to this, the emerging popularity of outpatient rehabilitation programs, which allow individuals to live at home while receiving regular treatment, such as therapy or medication-assisted treatment (MAT), is further creating a positive outlook for the market. Moreover, several government bodies across the globe are taking initiatives to create awareness and understanding of SUD as a treatable medical condition, thus reducing the stigma associated with it and encouraging more people to seek treatment. This, in turn, is acting as a significant growth-inducing factor. Apart from this, the introduction of private insurance coverage for substance abuse disorder treatment, which has made it easier for individuals to access and afford the medicament, is also propelling the global market. Additionally, the escalating utilization of holistic therapeutic approaches, such as yoga, meditation, acupuncture, etc., in combination with traditional SUD treatments to address the physical, emotional, and spiritual aspects of substance abuse is further bolstering the market growth. Besides this, the widespread adoption of behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, which help in identifying and changing negative thought patterns and behaviors related to substance abuse, is expected to drive the global substance use disorder market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the substance use disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the substance use disorder market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the substance use disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the substance use disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current substance use disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the substance use disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the substance use disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the substance use disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of substance use disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of substance use disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of substance use disorder by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of substance use disorder by type across the seven major markets?
How many patients are diagnosed (2018-2034) with substance use disorder across the seven major markets?
What is the size of the substance use disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of substance use disorder?
What will be the growth rate of patients across the seven major markets?

Substance Use Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for substance use disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the substance use disorder market?
What are the key regulatory events related to the substance use disorder market?
What is the structure of clinical trial landscape by status related to the substance use disorder market?
What is the structure of clinical trial landscape by phase related to the substance use disorder market?
What is the structure of clinical trial landscape by route of administration related to the substance use disorder market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Substance Use Disorder - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Substance Use Disorder - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Substance Use Disorder - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Substance Use Disorder - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Substance Use Disorder - Unmet Needs

10 Substance Use Disorder - Key Endpoints of Treatment

11 Substance Use Disorder - Marketed Products
11.1 List of Substance Use Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Campral (Acamprosate)
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Revia (Naltrexone)
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Subutex (Buprenorphine extended-release) - Indivior
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Substance Use Disorder - Pipeline Drugs
12.1 List of Substance Use Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 Psilocybin - Clairvoyant Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 DMX-1002 - DemeRx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Naltrexone intranasal - Opiant Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 INDV2000 - Indivior
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ASP8062 - Astellas Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Substance Use Disorder - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Substance Use Disorder – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Substance Use Disorder - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Substance Use Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Substance Use Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Substance Use Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Substance Use Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Substance Use Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Substance Use Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Substance Use Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Substance Use Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Substance Use Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Substance Use Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Substance Use Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Substance Use Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Substance Use Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Substance Use Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Substance Use Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Substance Use Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Substance Use Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Substance Use Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Substance Use Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Substance Use Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Substance Use Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Substance Use Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Substance Use Disorder - Access and Reimbursement Overview

16 Substance Use Disorder - Recent Events and Inputs From Key Opinion Leaders

17 Substance Use Disorder Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Substance Use Disorder Market – Strategic Recommendations

19 Appendix